STAT3 Inhibitor Prodrugs With Improved Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing STAT3 inhibitors like TTI-101 face challenges with low solubility and stability, making it difficult to formulate effective pharmaceutical compositions for treating cancer, fibrosis, and inflammatory diseases.
Innovation Solution
Development of compounds of Formula I, which include specific substituents and structures to enhance solubility and stability, providing improved chemical stabilization and maintaining comparable pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TTI-101 is used as a STAT3 inhibitor, then STAT3 inhibition activity is achieved, but solubility and stability are poor
Solution Approach 1:
The patent modifies the chemical structure of TTI-101 by changing parameters such as introducing ester groups at specific positions (e.g., positions 3 and/or 4 of the binaphthalene core) to alter solubility and stability parameters while maintaining STAT3 inhibition activity. This structural parameter change enables better pharmaceutical formulation.
Solution Approach 2:
The invention creates composite molecular structures by combining the binaphthalene core with ester functional groups and other moieties to form compounds of Formula I. These composite structures exhibit both the desired STAT3 inhibition activity and improved solubility/stability properties.
2Reliability
If TTI-101 is used for treating cancer, fibrosis, and inflammatory diseases, then therapeutic efficacy is achieved, but formulation difficulty increases due to low solubility and stability
Solution Approach 1:
By changing the chemical parameters of TTI-101 through structural modification (introduction of ester groups, carbamate groups, or other functional moieties), the patent improves solubility and stability parameters, making the compound suitable for pharmaceutical formulation and clinical application in cancer, fibrosis, and inflammatory diseases.
Solution Approach 2:
The patent introduces intermediary functional groups (ester groups, carbamate groups) that act as mediators between the binaphthalene core and the pharmaceutical formulation system. These intermediary groups improve compatibility with formulation excipients and enhance bioavailability.
3Productivity
If prodrugs of TTI-101 are developed to improve solubility and stability, then pharmacokinetic properties are enhanced, but compound complexity increases
Solution Approach 1:
The patent systematically modifies structural parameters of TTI-101 by introducing ester groups at specific positions (3 and/or 4 of binaphthalene) and varying substituents (R1-R6 groups) to optimize pharmacokinetic properties while managing structural complexity through a systematic approach.
Solution Approach 2:
The patent segments the modification process into discrete positional variations (position 3, position 4, both positions) and substituent types (ester groups with different R groups), allowing systematic exploration of structure-activity relationships and pharmacokinetic optimization without overwhelming complexity.
Data Source
AI summary
Provided herein, in certain embodiments, are compounds of Formula I:or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).